Redx Pharma plc Issue of Warrants and Change to Lease Agreement (3457R)
28 February 2019 - 6:01PM
UK Regulatory
TIDMREDX
RNS Number : 3457R
Redx Pharma plc
28 February 2019
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company")
Issue of Warrants and Change to Lease Agreement
Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that, as previously noted in its 2018 Annual Report, it
has successfully completed an agreement with Alderley Park Limited
to significantly reduce its accommodation footprint in the
Company's Headquarters at Alderley Park, Cheshire.
As part of the agreement, on 27 February 2019, a Warrant to
acquire 750,000 ordinary shares of 1p each in the share capital of
the Company was issued to Alderley Park Limited as follows:
The subscription price payable per warrant share on exercise of
the warrant is:
Price No. of Shares Date of Vesting
13.75p 125,000 27 February 2019
------------------------------------- ----------------------------------------
20p 125,000 27 February 2019
------------------------------------- ----------------------------------------
27p 125,000 27 February 2020
------------------------------------- ----------------------------------------
35p 125,000 27 February 2020
------------------------------------- ----------------------------------------
42.5p 125,000 27 February 2021
------------------------------------- ----------------------------------------
50p 125,000 27 February 2021
------------------------------------- ----------------------------------------
The Warrant will not become exercisable until the second
anniversary of issue.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded
on AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKODKFBKDFBB
(END) Dow Jones Newswires
February 28, 2019 02:01 ET (07:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024